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ABSTRACT
Objective To investigate the long-term prognostic
implications of coronary calcification in patients
undergoing percutaneous coronary intervention for
obstructive coronary artery disease.
Methods Patient-level data from 6296 patients
enrolled in seven clinical drug-eluting stents trials were
analysed to identify in angiographic images the presence
of severe coronary calcification by an independent
academic research organisation (Cardialysis, Rotterdam,
The Netherlands). Clinical outcomes at 3-years follow-up
including all-cause mortality, death—myocardial
infarction (MI), and the composite end-point of all-cause
death—MI—any revascularisation were compared
between patients with and without severe calcification.
Results Severe calcification was detected in 20% of
the studied population. Patients with severe lesion
calcification were less likely to have undergone complete
revascularisation (48% vs 55.6%, p<0.001) and had an
increased mortality compared with those without
severely calcified arteries (10.8% vs 4.4%, p<0.001).
The event rate was also high in patients with severely
calcified lesions for the combined end-point death—MI
(22.9% vs 10.9%; p<0.001) and death—MI— any
revascularisation (31.8% vs 22.4%; p<0.001). On
multivariate Cox regression analysis, including the Syntax
score, the presence of severe coronary calcification was
an independent predictor of poor prognosis (HR: 1.33
95% CI 1.00 to 1.77, p=0.047 for death; 1.23, 95%
CI 1.02 to 1.49, p=0.031 for death—MI, and 1.18,
95% CI 1.01 to 1.39, p=0.042 for death—MI— any
revascularisation), but it was not associated with an
increased risk of stent thrombosis.
Conclusions Patients with severely calcified lesions
have worse clinical outcomes compared to those without
severe coronary calcification. Severe coronary calcification
appears as an independent predictor of worse prognosis,
and should be considered as a marker of advanced
atherosclerosis.
INTRODUCTION
From the early days of percutaneous coronary
intervention (PCI) it became apparent that the
presence of severe coronary calcification was a
predictor of worse clinical outcomes. In the era of
plain old balloon angioplasty, severe coronary calci-
fication was associated with an increased risk of
coronary dissection and procedural failure, while in
the bare-metal stent era, it was associated with a
higher incidence of in-stent restenosis and target
lesions revascularisations (TLR).1 2 The advent of
drug-eluting stents (DES) changed the landscape
of coronary intervention through the reduced risk
of restenosis and TLR, thereby allowing the inter-
ventional treatment of complex lesions and
high-risk patients. Several studies have examined
the efficacy of DES in heavily calcified lesions
reporting mixed results. Some have demonstrated a
high success rate and a marked reduction in TLR,
while others have reported that patients with calci-
fied lesions undergoing PCI with DES have a
higher incidence of stent thrombosis (ST) and an
increased major adverse event rate, compared to
the event rate reported in patients without coron-
ary calcification.3–8 However, all the previous
studies included a small number of patients with
few events,4 7 8 whereas only one has reported the
prognostic implications of lesion calcium in patients
treated with a second-generation DES.4
The aim of the current analysis is to examine the
effect of coronary calcification on hard clinical end-
points in patients treated with a first or second-
generation DES.
METHODS
Studied population
We retrospectively analysed data from patients
implanted with a DES who were recruited in the fol-
lowing stent trials: the ARTS II (Arterial
Revascularisation Therapies Study II), the LEADERS
(Limus Eluted From a Durable vs Erodable Stent
Coating) trial, the MULTISTRATEGY (Multicenter
Evaluation of Single High-Dose Bolus Tirofiban vs
Abciximab With Sirolimus-Eluting Stent or
Bare-Metal Stent in Acute Myocardial Infarction
(MI)) study, the STRATEGY (Single High-Dose Bolus
Tirofiban and Sirolimus-Eluting Stent vs Abciximab
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and Bare-Metal Stent in Myocardial Infarction) trial, the SIRTAX
(Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent
for Coronary Revascularization), the SYNTAX (Synergy Between
Percutaneous Coronary Intervention with Taxus and Cardiac
Surgery) and the RESOLUTE (Resolute All Comers) trial. The aim
and inclusion criteria were different between studies: two trials
included stable patients with complex coronary artery disease and
aimed to compare outcomes between patients treated with PCI or
bypass surgery (the SYNTAX and the ARTS II), two evaluated the
efficacy of DES treatment combined with different IIb/IIIa inhibi-
tors in patients admitted with an acute MI (the STRATEGY and
MYLTISTRATEGY trial), the SIRTAX assessed the effectiveness of
two first-generation DES devices in patients with obstructive cor-
onary artery disease that was amenable to PCI, the LEADERS
compared a DES with a biodegradable polymer to a first-
generation DES in patients with coronary artery disease and,
finally, the RESOLUTE all-comers compared two second-
generation DES with different drug elution in an unselected
patient population which was representative of patients treated in
everyday clinical practice. A detailed description of each study
design has been reported elsewhere.9–15 All studies complied with
the Declaration of Helsinki, and were approved by the ethical
review board of the institution involved, whereas, the included
patients provided written informed consent for participation in
these studies.
Data processing
The baseline demographic data and the X-ray angiographic data
of the patients recruited in these studies were transferred to an
independent academic research organisation (Cardialysis,
Rotterdam, The Netherlands) for further processing. Two
trained analysts reviewed the angiographic films; they calculated
the Syntax score using a previously described methodology, and
identified the presence of severely calcified lesions defined as:
radiopacities noted without cardiac motion before contrast
injection, generally compromising both sides of the arterial
lumen.16 17 In case of disagreement, the opinion of a third
expert analyst was requested, and the final decision was
obtained by consensus. At the time of the angiographic analysis,
the reviewers were blinded to the patients’ demographic
characteristics and clinical outcomes.
Clinical end-points and definitions
All the studied patients were followed-up for at 3 years. The
primary end-point of this analysis was all-cause mortality at
3 years follow-up. Secondary end-points of this analysis were the
combined end-points for death—all MIs (ST-elevation and
non-ST-elevation MI)—and the composite end-point for—MI—
any revascularisation. As it has been previously reported, there was
an inconsistency in the definition of ST-elevation and
non-ST-elevation MI among the different studies, which can be
attributed to the different populations included in each study, the
different study designs, and the different periods when the trials
were conducted.18 Considering the fact that the events reported in
each trial were reviewed by an independent clinical event commit-
tee a decision was taken not to readjudicate MI using a uniform
definition and, instead, all MIs are defined as per the individual
study protocol definition. Revascularisation follow-up data were
available in only 4 (ARTS II, SYNTAX, LEADERS, and
RESOLUTE) studies and, thus, the combined end-point all-cause
mortality—any MI—any revascularisation was reported only for
the patients recruited in these studies.
Additionally, the ST events were recorded and compared in
the two groups. ST was classified as definite, probable and
possible, according to the Academic Research Consortium defi-
nitions.19 Definite ST data were available in six studies (ARTS
II, SYNTAX, LEADERS, RESOLUTE, MULTISTRATEGY and
SIRTAX), probable ST data in 5 (ARTS II, SYNTAX, LEADERS,
RESOLUTE, and MULTISTRATEGY), and the possible in
4 (ARTS II, SYNTAX, LEADERS, and RESOLUTE) out of the
seven clinical trials.
Statistics
Numerical variables are presented as median with 25th and
75th percentiles while categorical variables are presented as
absolute values and percentages. The studied patients were cate-
gorised into those with severely calcified coronary lesions and
those without severe lesion calcification. Comparisons between
the two groups were performed using the Mann–Whitney U test
for the continuous variables, and the χ2 test for the categorical
variables.
Cox regression analysis was used to identify predictors of
adverse events, that is, all-cause mortality,—MI, death—MI—any
revascularisation, and ST. The hazard ratio (HR) and the 95% con-
fidence interval (CI) for the continuous variables were estimated
per unit increase. The estimates from the univariate analysis pre-
dictors of worse prognosis were entered into a multivariable
model to identify independent predictors of worse outcomes. In
the multivariable models, the ‘forced enter’ method was deemed
appropriate. To address the clustering effect, shared frailty models
were used in univariate and multivariate analyses. To exclude
colinearity, we identified the variables that were highly correlated
(r>0.5 and p<0.05), and we included in the model only those
variables that had a higher level of prognostic significance.
The proportionality of hazards assumption was examined by
residual plotting. Graphical plots were made by the Kaplan–Meier
method. The log-rank statistic was used to compare prognosis
between the two groups. A p value <0.05 (two-tailed) was consid-
ered statistically significant. Data analysis was performed using the
Statistical Package for Social Sciences (SPSS) V.18.0 (SPSS,
Chicago, Illinois, USA) and the STATA V.12.0 software (Stata,
College Station, Texas, USA).
RESULTS
Baseline demographics
The Syntax score, and the clinical and the follow-up data were
available for 6296 patients out of the 7639 patients that were
enrolled in the seven clinical trials. Most of the studied patients
were male with a history of hypertension and hypercholesterol-
aemia and were admitted because of an acute coronary event.
Four out of 10 patients were treated with a first-generation DES
(ie, a sirolimus or paclitaxel-eluting stent), and six out of
10 patients with a second-generation device (ie, an everolimus,
zotarolimus, or a biolimus-eluting platform).
Twenty per cent of the studied patients had severely calcified
lesions on coronary angiography (table 1). These patients were
older and were more likely to suffer from hypertension and hyper-
cholesterolaemia compared to the group of patients without
severe lesion calcium who were more often diabetic. Patients with
severe calcification had a higher Syntax score (12.1 units higher
than those without severe calcification, 95% CI 11.5 to 12.7;
p<0.001), and were less likely to have undergone complete revas-
cularisation (data with regards complete revascularisation was
available only for the ARTS II the STRATEGY, MULTISTRATEGY
and the SYNTAX study). No differences were noted between the
two groups with regards to the cause of admission, the incidence
of LV systolic dysfunction, and the prevalence of peripheral vascu-
lar disease (PVD).
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Severe lesion calcification and clinical end-points
All studied patients were followed-up for 3 years. During
follow-up, 359 (5.7%) patients died, of whom 139 had severely
calcified lesions (table 2). The Kaplan–Meier analysis showed
that patients with severely calcified lesions had significantly
higher all-cause mortality (10.8% vs 4.4%, log-rank test=79.35;
p<0.001) compared to those without. Landmark analysis
showed an increased mortality in the group of patients with
severely calcified lesions at 1 year post-procedure, and also for
the period between 1 and 3 years follow-up (figure 1A).
Severe calcification appeared as a predictor of increased mor-
tality in the univariate Cox regression analysis (HR: 2.41, 95%
CI 1.92 to 3.00; p<0.001). Table 3 shows all the predictors of
all-cause mortality identified by univariate Cox regression ana-
lysis. In the multivariate model, that included all the independ-
ent predictors of worse outcomes, apart from the history of
cerebrovascular disease and PVD because of missing data, the
presence of calcified lesions was independently associated with
an increased all-cause mortality (table 3).
The combined end-point death—MI was reported in 840
patients. Patients with severe lesion calcification were at a higher
risk of experiencing an event compared to those without calci-
fied lesions (23.2% vs 11.0%; log-rank=130.29; p<0.001).
Landmark analysis showed a worse prognosis in the group of
patients with severely calcified lesions at the first year post-
procedure, but also for the period between 1 and 3 years
follow-up (figure 1B).
In univariate Cox regression analysis, severe calcification was
a predictor of death—MI (HR: 1.86, 95% CI 1.60 to 2.16;
p<0.001). In the multivariate model built, excluding the history
of cerebrovascular and PVD, severe calcification was a predictor
of death—MI (table 4).
Outcome data with regards the combined end-point death—
MI—any revascularisation was available in 5018 patients. At
3-year follow-up, 1213 events were reported, of which 860
(22.4%) occurred in patients without severely calcified lesions,
and 373 (31.8%) in patients with severe lesion calcification
(log-rank=14.55; p<0.001, figure 1C). Similarly to what has
been reported for the other end-points, landmark analysis
showed a worse outcome in the group of patients with severely
calcified lesions at 1 year post-procedure, and also for the
period between 1 and 3 years follow-up (figure 1C). Severe
lesion calcification was a predictor of worse outcome in univari-
ate and multivariate Cox regression analysis (table 5).
During follow-up, 269 ST events occurred, of which 129
were definite, 43 probable and 97 possible ST (table 3). Patients
with calcified coronaries had an increased incidence of ST
Table 1 Baseline demographics of the patients with and without severely calcified lesions
All studied patients
(n=6296)
Patients with severely calcified
lesions (n=1291)
Patients without severe
calcifications (n=5005) p Value
Age (years) 64 (56–72) 69 (62–75) 63 (55–71) <0.001
Male (%) 4740 (75.3) 957 (74.1) 3783 (75.6) 0.280
BMI 27.1 (24.7–30.0) 27.0 (24.2–30.0) 27.2 (24.8–30.1) 0.001
Hypertension 4328 (69.4) 969 (75.5) 3359 (67.7) <0.001
Hypercholesterolaemia (%) 4056 (65.2) 899 (70.2) 3157 (63.9) <0.001
Diabetes mellitus (%) 1453 (23.2) 1079 (21.7) 374 (29.0) <0.001
Peripheral vascular disease (%) 1745 (30.7) 397 (32.1) 1348 (30.3) 0.214
Cerebrovascular disease (%) 182 (4.9) 73 (7.2) 109 (4.0) <0.001
Creatinine > 200 mol/L 61 (1.1) 20 (1.6) 41 (0.9) 0.025
Positive smoking history (%) 3257 (52.1) 648 (50.4) 2609 (52.6) 0.161
LV systolic function 0.712
Normal LV function (%) 3838 (78.4) 833 (77.6) 3005 (78.7)
Moderate LV dysfunction (%) 865 (17.7) 196 (18.2) 669 (17.5)
Severe LV dysfunction (%) 191 (3.9) 45 (4.2) 146 (3.8%)
Unstable presentation (%) 3349 (53.2) 672 (52.1) 2677 (53.5) 0.357
History of previous MI (%) 1745 (30.7) 397 (32.1) 1348 (30.3) 0.214
Syntax score 15 (9–23) 25 (18–34) 13 (7–20) <0.001
Complete revascularisation (%) 1086 (53) 339 (48) 550 (55.6) 0.001
Treatment with 2nd generation DES (%) 2709 (43.0) 375 (29.0) 2334 (46.5) <0.001
BMI, Body Mass Index; MI, myocardial infarction; DES, drug-eluting stent.
Table 2 Reported events in the studied patients at a follow-up
period of 3 years
All
studied
patients
(n=6296)
Patients with
severely
calcified
lesions
(n=1291)
Patients
without
severe
calcifications
(n=5005)
Death (%) 359 (5.7) 139 (10.8) 220 (4.4)
MI (%) 551 (8.8) 183 (14.2) 368 (7.4)
Any revascularisation* (%) 866 (17.3) 241 (20.5) 625 (16.3)
Combined end-points
Death—MI (%) 840 (13.3) 295 (22.9) 545 (10.9)
Death—MI-any (%)
revascularisation*
1213 (24.2) 373 (31.7) 860 (22.4)
Stent thrombosis†
Definite (%) 129 (2.1) 38 (3.0) 91 (1.8)
Probable (%) 43 (0.8) 16 (1.3) 27 (0.7)
Possible (%) 97 (1.9) 35 (3.0) 62 (1.6)
*Revascularisation data were available in 5018 patients (1175 with severely calcified
lesions and 3843 in patients without severe coronary calcification).
†Definite stent thrombosis data were available in 6222 patients (1279 with severe
lesion calcification and 4943 without calcified coronaries), probable stent thrombosis
in 5364 (1221 with severely calcified coronaries and 4143 without severe coronary
calcification) and possible in 5034 patients (1182 with severe and 3852 without
severe coronary calcification).
MI, myocardial infarction.
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compared to those without coronary calcification (definite ST:
3% vs 1.8%, log-rank=6.97; p=0.008; definite/probable ST:
4.3% vs 2.1%, log-rank=17.06, p<0.001). Severe lesion calcifi-
cation was a predictor of ST in univariate analysis (definite ST:
HR: 1.66, 95% CI 1.13 to 2. 42; p<0.001; definite/probable
ST: HR: 1.95, 95% CI 1.37 to 2.76; p<0.001), but it was not
an independent predictor in the multivariate models (definite
ST: HR: 1.41, 95% CI 0.87 to 2.28; p=0.167; definite/prob-
able ST: HR: 1.40, 95% CI 0.91 to 2.15; p=0.124).
DISCUSSION
This retrospective analysis provides additional evidence about
the prognostic implications of lesion calcium in patients under-
going PCI. We found that severe lesion calcification is an
Figure 1 Kaplan–Meier and landmark analysis for the all-cause mortality (A, B), death—myocardial infarction (C, D) and for the combined
end-point death—myocardial infarction-any revascularisation (E, F) in patients with and without severe lesion calcification. The landmark analysis
was performed for the first year and for the period 1–3 years follow-up.
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independent predictor of worse outcomes, and its presence
appears to provide additional prognostic information from the
Syntax score which reflects coronary artery disease complexity.
Several studies in the past have examined the prognostic
implications of lesion calcification in the DES era. Moussa et al3
were the first to show a significant reduction in TLR with
paclitaxel-eluting stents compared to bare-metal stents, and no
difference in the incidence of TLR between calcified and non-
calcified lesions treated with a DES. Kawaguchi et al7 showed a
higher risk of in-stent restenosis in calcified lesions but no differ-
ence in the incidence of adverse cardiovascular events; however,
the small number of patients included in this analysis (n=380),
and the lack of multivariate analysis, does not allow us to draw
firm conclusions. More recent studies, however, have shown
that lesion calcification is associated with an increased risk of
cardiovascular events, and provided robust evidence about its
prognostic implications.6 8 In all these reports, the patients were
mainly treated with a first-generation DES, the prognostic
implications of lesion calcification in these studies has been asso-
ciated with the complexity of the PCI, while the Syntax score
which reflects more accurately the anatomical complexity of the
lesion was not available.
In this study, we examined for the first time the prognostic
implications of lesion calcification in a large group of patients
treated with either a first or a second-generation DES.
Importantly, we have a reliable and reproducible assessment of
lesion complexity as we included in this analysis only the
patients that had Syntax score evaluation. We found that lesion
calcification provided additional prognostic information as it
was an independent predictor of all-cause mortality, death—MI
and death—MI—any revascularisation. The fact that the
patients with severely calcified lesions have worse prognosis at
short term (ie, within the first year post-procedure), and also at
long-term follow-up, indicates that the poor outcome in this
group of patients is not only related to periprocedural
complications.
Table 3 Univariate and multivariate Cox regression analysis of variables associated with increased all-cause mortality.
Univariate Cox regression Multivariate Cox regression*
HR (95% CI) p Value HR (95% CI) p Value
Increasing age (per decade) 2.02 (1.81 to 2.25) <0.001 1.76 (1.54 to 2.01) <0.001
Female gender 1.33 (1.07 to 1.67) 0.011 1.11 (0.85 to 1.46) 0.438
Comorbidities
History of diabetes mellitus 1.85 (1.49 to 2.29) <0.001 1.60 (1.24 to 2.06) <0.001
History of hypertension 1.30 (1.03 to 1.65) 0.029 1.00 (0.74 to 1.35) 0.991
Absence of history of hypercholesterolaemia 1.41 (1.14 to 1.74) 0.002 1.16 (0.89 to 1.52) 0.258
History of peripheral vascular disease* 2.59 (1.80 to 3.63) <0.001 –
History of cerebrovascular disease* 1.96 (1.26 to 3.03) <0.001 –
Increased creatinine (>200 mol/L) 7.23 (4.60 to 11.36) <0.001 3.37 (1.87 to 5.64) <0.001
LV systolic dysfunction 2.17 (1.83 to 2.59) <0.001 1.81 (1.50 to 2.19) <0.001
Previous history of myocardial infarction 1.24 (1.00 to 1.55) 0.052 1.21 (0.93 to 1.56) 0.154
Angiographic variables
Syntax score (per unit) 1.04 (1.03 to 1.05) <0.001 1.02 (1.01 to 1.03) <0.001
Severe lesion calcification 2.41 (1.92 to 3.00) <0.001 1.33 (1.00 to 1.77) 0.047
*Because of missing data, the history of cerebrovascular and peripheral vascular diseases were not entered into the multivariate analysis.
Table 4 Univariate and multivariate Cox regression analysis of variables associated with the combined end-point death—myocardial infarction
Univariate Cox regression Multivariate Cox regression*
HR (95% CI) p Value HR (95% CI) p Value
Increasing age (per decade) 1.36 (1.28 to 1.45) <0.001 1.28 (1.18 to 1.39) <0.001
Female gender 1.24 (1.07 to 1.44) 0.004 1.08 (0.90 to 1.30) 0.402
Comorbidities
History of diabetes mellitus 1.55 (1.34 to 1.80) <0.001 1.45 (1.22 to 1.71) <0.001
History of hypertension 1.20 (1.03 to 1.40) 0.021 1.00 (0.82 to 1.21) 0.994
History of peripheral vascular disease* 1.85 (1.46 to 2.35) <0.001 –
History of cerebrovascular disease* 1.70 (1.26 to 2.29) 0.001 –
Increased creatinine (> 200 mol/L) 4.01 (2.75 to 5.85) <0.001 2.56 (1.64 to 3.99) <0.001
LV systolic dysfunction 1.57 (1.38 to 1.78) <0.001 1.36 (1.18 to 1.56) <0.001
History of previous myocardial infarction 1.21 (1.04 to 1.40) 0.011 1.15 (0.97 to 1.36) 0.113
Angiographic variables
Syntax score (per unit) 1.03 (1.02 to 1.04) <0.001 1.02 (1.01 to 1.03) <0.001
Severe lesion calcification 1.86 (1.60 to 2.16) <0.001 1.23 (1.02 to 1.49) 0.031
*Because of missing data, the history of cerebrovascular and peripheral vascular disease was not entered into the multivariate analysis.
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A potential explanation of this finding is that coronary calcifi-
cation is a marker of extensive atherosclerotic disease. Indeed,
several electron beam-computed tomography-based studies have
shown that coronary calcification is a predictor of atheroscler-
osis progression and is related with increased cardiovascular
mortality in the general population.20 21 However, in patients
undergoing PCI, the focus has been towards the development of
anatomical scores that would allow accurate assessment of lesion
complexity, or the implications of the lesion on myocardial per-
fusion and the prognostic value of coronary calcification has
been ignored.16 22 The present study convincingly demonstrates
that severe lesion calcification provides additional information
which, until today, has been neglected and not been taken into
consideration in the prognostic models developed for patients
undergoing PCI.23 24
Severe lesion calcification appeared to be associated with an
increased risk of ST in univariate analysis, but it was not an
independent predictor of ST. Our results are different from the
findings of other reports which showed that lesion calcification
is independently associated with an increased risk of ST,5 6 but
are similar to the findings of the SYNTAX study, that included
the Syntax score, which can compete with lesion calcification in
the multivariate model.25 Nevertheless, the fact that this study
did not include procedural information (ie, number of
implanted stents, length and diameter of stents, etc), lesion
characteristics (ie, length of the lesion, vessel diameter, the
number of the bifurcated lesions), and the type and duration of
antiplatelet treatment, does not allow us to draw firm conclu-
sions about the factors related to ST.
We have recently demonstrated that patients suffering from
coronary artery disease with severely calcified lesions are more
likely to receive suboptimal revascularisation and have a higher
residual Syntax score which is a powerful determinant of prog-
nosis.26 Additionally, in this study, we found that patients with
severely calcified lesions are less likely to have undergone com-
plete revascularisation. A decalcification strategy with extensive
metallic stent implantation cannot be justified as there is robust
evidence that stent length is a predictor of TLR. On the other
hand, bioresorbable scaffolds appear to overcome the limitations
of the traditional metallic stents and seem to have a role for the
treatment of heavily calcified lesions.27 Whether complete revas-
cularisation—implementing a decalcification strategy of long-
calcified lesions with atherectomy, or the recently introduced
orbital atherectomy system followed by bioresorbable scaffold
implants—would improve outcomes in this high-risk popula-
tion, needs to be proven by future studies.28
Study limitations
Several intravascular imaging studies have shown that coronary
angiography has a limited sensitivity in detecting the presence
of calcified plaques.17 29 However, it has a high specificity for
detecting severe calcification, and has been shown in this study
to provide useful prognostic information. By contrast with pre-
vious studies which implemented a more thorough classification
scheme for characterising lesion calcification, we decided to clas-
sify patients in a binary fashion to those who have lesions with
none/mild/moderate calcification, and those with severe calcifi-
cation. Although this may be regarded initially as a limitation of
the current analysis, our decision was based on the low intraob-
server and interobserver variability reported for the discrimin-
ation between none/mild and moderate/severe calcification.30 Of
note, Genereux et al31 have shown that experts can identify and
differentiate with a high agreement severely calcified lesions
from the other lesions; based on these findings, we decided to
use a reproducible metric and divide patients based on the pres-
ence of severe calcification.
Finally, a significant limitation of this study is the fact that the
medications data, such as the type of medications, the doses and
the duration of treatment (especially the duration of dual anti-
platelet treatment), as well as procedural data (ie, treatment of
bifurcation lesions, length of the lesions, vessel diameter,
number of implanted stents, dimensions of the stents, etc) were
not available.
CONCLUSIONS
Patients with severely calcified lesions are at a high risk of
experiencing a cardiovascular event. Severe lesion calcification
appears to provide additional prognostic information to the
Syntax score, which reflects lesion complexity, because it is a
marker of extensive atherosclerosis, and because patients with
severely calcified lesions do not receive complete revascularisa-
tion. Further research is needed to explore whether a decalcifi-
cation strategy and complete revascularisation of these high-risk
patients would have a beneficial effect on their prognosis.
Table 5 Univariate and multivariate Cox regression analysis of variables associated with death—myocardial infarction—any revascularisation.
Univariate Cox regression Multivariate Cox regression*
HR (95% CI) p Value HR (95% CI) p Value
Increasing age (per decade) 1.14 (1.08 to 1.20) <0.001 1.08 (1.02 to 1.16) 0.013
Comorbidity
History of diabetes mellitus 1.52 (1.35 to 1.72) <0.001 1.42 (1.23 to 1.64) <0.001
History of hypertension 1.23 (1.08 to 1.40) 0.002 1.07 (0.91 to 1.25) 0.431
History of peripheral vascular disease* 1.44 (1.15 to 1.82) 0.002 –
Increased creatinine (>200 mol/L) 2.76 (1.91 to 3.99) <0.001 2.04 (1.33 to 3.14) 0.001
LV systolic dysfunction 1.25 (1.11 to 1.41) <0.001 1.15 (1.02 to 1.31) 0.026
Previous history of myocardial infarction 1.17 (1.04 to 1.32) 0.010 1.07 (0.93 to 1.23) 0.335
Angiographic variables
Syntax score (per unit) 1.03 (1.02 to 1.03) <0.001 1.03 (1.02 to 1.03) <0.001
Severe lesion calcification 1.52 (1.34 to 1.72) <0.001 1.18 (1.01 to 1.39) 0.042
First generation stent 1.15 (0.98 to 1.35) 0.091 1.13 (0.90 to 1.41) 0.289
*Because of missing data, the history of peripheral vascular disease was not entered into the multivariate analysis.
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Key messages
What is known on this subject?
There is strong evidence demonstrating that lesion calcium is
associated with an increased risk of target vessel
revascularisation following bare-metal or drug-eluting stent
implantation. However, there are limited data regarding the
impact of lesion calcium on hard clinical end-points in the
drug-eluting stents era.
What might this study add?
This study shows that the patients with severely calcified lesions
who undergo percutaneous coronary intervention (PCI) with a
first-generation or a second-generation drug-eluting stent often
undergo incomplete revascularisation and have worse clinical
outcomes compared to those without severe coronary
calcification.
How might this impact on clinical practice?
All the previous risk models that were designed to predict prognosis
in patients undergoing PCI did not take into account lesion
calcification. This study is anticipated to trigger the re-evaluation of
the existing risk scores and the design of new models that would
predict patients’ prognosis with a higher accuracy.
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